Supplemental methods, supplemental tables 1-4, and supplemental figures 1-14 from BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation

<p>Table S1. The list of the SCLC cell lines (N=52) used in this study. Table S2. The list of 384 genes that constitute the NEUROD1 gene signature. Table S3. The siRNA screen results in H446 and COR-L279 cells. Table S4. Sensitivity (IC50) of SCLC lines (N=52) to JQ1 and NHWD-870. Figure S1. Knockout of NEUROD1 by CRISPR in H446 cells. Figure S2. Validation of the H446 NEUROD1 ChIP-seq. Figure S3. BET bromodomain proteins interact with NEUROD1 in H524 cells. Figure S4. BRD4 interacts with ASCL1 in H1963 cells. Figure S5. NEUROD1 KO affects the BRD4 occupancy only in the genomic regions co-occupied by NEUROD1. Figure S6. Neuronal-related pathways are enriched among the NEUROD1-target genes in H446 cells. Figure S7. Validation of the NEUROD1 gene signature using the SCLC RNA-seq dataset in the CCLE. Figure S8. Effects of BETi on NEUROD1 gene expression in H446 cells. Figure S9. The NEUROD1- and BRD4-loaded SEs identified in H446 control and NEUROD1-KO cells and their correlation. Figure S10. The SCLC-N lines are more susceptible to BETi. Figure S11. NEUROD1 KO renders DMS-273 cells resistant to BETi. Figure S12. Effects of NEUROD1 KO on MYC expression and transactivation. Figure S13. LSAMP expression is regulated by both NEUROD1 and BET bromodomain proteins. Figure S14. Correlation between the IC50 values of NHWD-870 and JQ1 in SCLC cell lines (N=28)</p>

Duke Scholars

Author Trudy G Oliver Pharmacology & Cancer Biology